Venous malformations has been shown to be the most common intracranial vascular malformation autopsy and clinical series. Cerebral venous malformation is associated with different frequnecies of epileptic seizures. Only in about 25% of cases are venous malformation diagnosed because of the occurrence of epileptic seizures. We report a case of 4 year-old female patient with status epilepticus caused by venous angioma in the right temporal lobe of the brain.
Autopsy ; Brain* ; Child, Preschool ; Epilepsy ; Female ; Hemangioma* ; Humans ; Status Epilepticus* ; Temporal Lobe ; Vascular Malformations

When a patient complains of gastrointestinal symptoms such as nausea, vomiting, and upper abdominal pain after ingestion of a substance such as a corrosive agent and certain drugs which can cause mucosal injury to the esophagus and stomach, we always keep in mind gastrointestinal injury and should perform an endoscopic procedure promptly and use the appropriate treatment. It is well known that common corrosive agents which can cause gastrointestinal injury are acidic and alkaline chemicals, and the common causative drug for gastrointestinal injury is NSAID. However, it is not well known that consuming hot food and drinks can cause gastrointestinal injury also. Up to now, there have only been a few case reports of esophageal mucosal injury due to the consumption of hot food and drinks. Gastric mucosal injury after ingesting hot food and drinks is rare and has not been reported often. So here, we report a case of gastric mucosal injury after ingesting a hot liquid diet via gastric feeding tube.
Abdominal Pain ; Diet ; Eating ; Enteral Nutrition ; Esophagus ; Hot Temperature ; Humans ; Nausea ; Stomach ; Vomiting

OBJECTIVE: We investigated the long-term efficacy, safety, and tolerability of aripiprazole in a large number of patients with schizophrenia, schizophreniform disorder, and schizoaffective disorder in Korea. METHODS: This was an open-label, multi-center, single-arm, 52-week study of patients with schizophrenia, schizophreniform disorder, and schizoaffective disorder. Korean patients (N=300) experiencing either a first episode or recurrence participated in this study. The primary efficacy measure was the Positive and Negative Syndrome Scale (PANSS) total score. Secondary efficacy measures included the PANSS positive and negative subscales, and the Clinical Global Impression-Severity of Illness (CGI-S). Safety was evaluated prospectively by recording treatmentemergent adverse events; measuring extrapyramidal symptoms (EPS), vital signs, and body weight; and performing laboratory tests. RESULTS: Overall, 55 (18.33%) of the patients completed the entire 52-week study. Treatment with aripiprazole provided rapid and significant improvement in all of the efficacy measures. Comparing PANSS total scores, PANSS positive subscale scores, and CGI-S scores, first-episode patients showed significant improvement than the patients who had experienced at least one recurrence. There were no significant differences in the mean change of EPS during the study, except for akathisia at week 8 and a significant decrease in serum prolactin level in patients experiencing first and recurrent episodes. At the end of the study, the mean weight gain was 2.40 kg. CONCLUSION: Aripiprazole is effective and safe for patients with schizophrenia, schizophreniform disorder, and schizoaffective disorder during a long-term, 52-week treatment. The result may be associated with the unique mechanism of aripiprazole. We have extended the findings of previous studies in the United States and other countries and demonstrated a similar effectiveness of aripiprazole for Korean patients.
Humans ; Piperazines ; Prolactin ; Prospective Studies ; Psychomotor Agitation ; Psychotic Disorders ; Quinolones ; Recurrence ; Schizophrenia ; United States ; Vital Signs ; Weight Gain ; Aripiprazole